An American company that is looking to develop new drugs to improve sexual desire in women with low libido announced that it needs more time to bring the drug, flibanserin, on to the market after reaching an impasse with the Food and Drug Administration.
Since women's sexual issues are more psychological, than physical, Sprout Pharmaceuticals said that the drug works by acting on brain chemicals connected to mood and appetite, Fox News reported.
Hair Loss in Women
Hair loss or Alopecia can be emotionally devastating to women but understanding reasons behind hair loss can help in prevention and treatment of hair loss.
Advertisement
Despite of women suffering from hypoactive sexual desire disorder reporting boost in sexual desire and reduction in stress with the drugs, the FDA has twice rejected flibanserin since 2010.
Cindy Whitehead, Sprout's chief operating officer, said that there are now
24 drugs for men for either testosterone replacement or erectile dysfunction, yet there are zero drugs for the most common form of sexual dysfunction in women.
The US firm acquired flibanserin from a German drugmaker in 2011, after they abandoned development of the daily pill following an FDA rejection.
Source: ANI
24 drugs for men for either testosterone replacement or erectile dysfunction, yet there are zero drugs for the most common form of sexual dysfunction in women.
The US firm acquired flibanserin from a German drugmaker in 2011, after they abandoned development of the daily pill following an FDA rejection.
Source: ANI
Women and Cancer
Cancer is one of the frequently talked about and most feared disease that falls under the genre of lifestyle diseases that have evolved, rather rapidly, in the past two decades.
Advertisement
 Breast Lumps in Women - Symptom EvaluationMost breast lumps are caused by hormonal changes in a woman and may not be cancerous. Keeping the threat of breast cancer in mind every breast lump should be medically evaluated. | Advertisement
|
Advertisement
Recommended Readings
Latest Women Health News
More than 90% of previously unexplained pregnancy losses or miscarriages were accurately determined by placental testing.
Fetal growth restriction impacts around 60,000 infants annually in Europe and the United States.
For women under 40, trying to conceive, timing intercourse around the fertile period using a urine ovulation test increases the chances of pregnancy.
Oophorectomy's adverse effects raise questions about risk-benefit balance, especially for average ovarian cancer risk women.
This study highlights the ovarian resilience achieved through stem cell treatments, providing hope for women struggling with fertility problems related to PCOS.
